{"id":{"repo_id":"strathclyde","oai_identifier":"oai:strathclyde:6h440s459"},"canonical_url":"https://search.dev.ndltd.org/etd/strathclyde/oai:strathclyde:6h440s459","repository":{"repo_id":"strathclyde","name":"University of Strathclyde","base_url":"https://stax.strath.ac.uk/catalog/oai"},"display":{"title":"Non-ionic surfactant vesicles as an Amphotericin B inhaled delivery system for the treatment of leishmaniasis","abstract":"Amphotericin B (AmB) is a drug used to treat visceral leishmaniasis and fungal infections. Current available AmB formulations are limited by instability at tropical temperature, parenteral administration, renal toxicity (Fungizone®) or cost (AmBisome®, Amphotec® and Abelcet®). In this study, inhaled AmB non-ionic surfactant vesicles (AmB-NIV) were assessed as an alternative AmB formulation, which should reduce costs, enhance drug bioavailability and stability and allow a non-invasive route of administration. AmB-NIV formulations (freshly prepared or lyophilised and non-ultra-filtrated or ultra-filtrated) were characterised on the basis of their vesicle size, ζ-potential, entrapment efficiency and viscosity. High performance liquid chromatography (HPLC) methods were validated and used to quantify the formulation constituents (AmB, cholesterol, surfactant and dicetyl phosphate) in stability studies. AmB-NIV formulations maintained stable at 37oC based on vesicle size, ζ-potential, entrapment efficiency and ingredients concentration up to 28 days. NIV enhanced drug delivery based on in vitro studies using a multi stage liquid impinger (MSLI) and should have lower toxicity based on the aggregation state of AmB. In vivo studies assessing the efficacy of inhaled AmB-NIV into a murine model of visceral leishmaniasis showed that 4 doses of inhaled AmB-NIV significantly reduced liver parasite burdens compared to the controls (p<0.05). Thus, NIV can be used to delivery AmB for the treatment of leishmaniasis by the pulmonary route but a multi-dose regimen is required.","abstract_html":"Amphotericin B (AmB) is a drug used to treat visceral leishmaniasis and fungal infections. Current available AmB formulations are limited by instability at tropical temperature, parenteral administration, renal toxicity (Fungizone®) or cost (AmBisome®, Amphotec® and Abelcet®). In this study, inhaled AmB non-ionic surfactant vesicles (AmB-NIV) were assessed as an alternative AmB formulation, which should reduce costs, enhance drug bioavailability and stability and allow a non-invasive route of administration. AmB-NIV formulations (freshly prepared or lyophilised and non-ultra-filtrated or ultra-filtrated) were characterised on the basis of their vesicle size, ζ-potential, entrapment efficiency and viscosity. High performance liquid chromatography (HPLC) methods were validated and used to quantify the formulation constituents (AmB, cholesterol, surfactant and dicetyl phosphate) in stability studies. AmB-NIV formulations maintained stable at 37oC based on vesicle size, ζ-potential, entrapment efficiency and ingredients concentration up to 28 days. NIV enhanced drug delivery based on in vitro studies using a multi stage liquid impinger (MSLI) and should have lower toxicity based on the aggregation state of AmB. In vivo studies assessing the efficacy of inhaled AmB-NIV into a murine model of visceral leishmaniasis showed that 4 doses of inhaled AmB-NIV significantly reduced liver parasite burdens compared to the controls (p&lt;0.05). Thus, NIV can be used to delivery AmB for the treatment of leishmaniasis by the pulmonary route but a multi-dose regimen is required.","abstract_has_math":false,"creators":["Puig-Sellart, Mireia"],"institution":"University of Strathclyde","degree_name":"mres","degree_level":"masters-pg","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-07-24T04:42:25Z","subjects":[],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["10.48730/8xfc-j642"],"render_values":[{"text":"10.48730/8xfc-j642","href":"https://doi.org/10.48730/8xfc-j642","code":true}]},{"key":"dc:identifier","label":"Identifier","values":["T13480"],"render_values":[{"text":"T13480","href":null,"code":true}]}]},"links":{"outbound_url":"https://stax.strath.ac.uk/concern/theses/6h440s459","outbound_label":"Repository record","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Puig-Sellart, Mireia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013"]},{"key":"dc:date.issued","label":"Date","values":["2013"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Strathclyde Institute of Pharmacy and Biomedical Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Strathclyde"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["masters-pg"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["mres"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["T13480"]},{"key":"dc:identifier.doi","label":"DOI","values":["10.48730/8xfc-j642"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://stax.strath.ac.uk/concern/theses/6h440s459"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Amphotericin B (AmB) is a drug used to treat visceral leishmaniasis and fungal infections. Current available AmB formulations are limited by instability at tropical temperature, parenteral administration, renal toxicity (Fungizone®) or cost (AmBisome®, Amphotec® and Abelcet®). In this study, inhaled AmB non-ionic surfactant vesicles (AmB-NIV) were assessed as an alternative AmB formulation, which should reduce costs, enhance drug bioavailability and stability and allow a non-invasive route of administration. AmB-NIV formulations (freshly prepared or lyophilised and non-ultra-filtrated or ultra-filtrated) were characterised on the basis of their vesicle size, ζ-potential, entrapment efficiency and viscosity. High performance liquid chromatography (HPLC) methods were validated and used to quantify the formulation constituents (AmB, cholesterol, surfactant and dicetyl phosphate) in stability studies. AmB-NIV formulations maintained stable at 37oC based on vesicle size, ζ-potential, entrapment efficiency and ingredients concentration up to 28 days. NIV enhanced drug delivery based on in vitro studies using a multi stage liquid impinger (MSLI) and should have lower toxicity based on the aggregation state of AmB. In vivo studies assessing the efficacy of inhaled AmB-NIV into a murine model of visceral leishmaniasis showed that 4 doses of inhaled AmB-NIV significantly reduced liver parasite burdens compared to the controls (p<0.05). Thus, NIV can be used to delivery AmB for the treatment of leishmaniasis by the pulmonary route but a multi-dose regimen is required."]},{"key":"dc:description.abstract","label":"Abstract","values":["Amphotericin B (AmB) is a drug used to treat visceral leishmaniasis and fungal infections. Current available AmB formulations are limited by instability at tropical temperature, parenteral administration, renal toxicity (Fungizone®) or cost (AmBisome®, Amphotec® and Abelcet®). In this study, inhaled AmB non-ionic surfactant vesicles (AmB-NIV) were assessed as an alternative AmB formulation, which should reduce costs, enhance drug bioavailability and stability and allow a non-invasive route of administration. AmB-NIV formulations (freshly prepared or lyophilised and non-ultra-filtrated or ultra-filtrated) were characterised on the basis of their vesicle size, ζ-potential, entrapment efficiency and viscosity. High performance liquid chromatography (HPLC) methods were validated and used to quantify the formulation constituents (AmB, cholesterol, surfactant and dicetyl phosphate) in stability studies. AmB-NIV formulations maintained stable at 37oC based on vesicle size, ζ-potential, entrapment efficiency and ingredients concentration up to 28 days. NIV enhanced drug delivery based on in vitro studies using a multi stage liquid impinger (MSLI) and should have lower toxicity based on the aggregation state of AmB. In vivo studies assessing the efficacy of inhaled AmB-NIV into a murine model of visceral leishmaniasis showed that 4 doses of inhaled AmB-NIV significantly reduced liver parasite burdens compared to the controls (p<0.05). Thus, NIV can be used to delivery AmB for the treatment of leishmaniasis by the pulmonary route but a multi-dose regimen is required."]},{"key":"dc:title","label":"Title","values":["Non-ionic surfactant vesicles as an Amphotericin B inhaled delivery system for the treatment of leishmaniasis"]}]}],"canonical_facts":{"dc:creator":["Puig-Sellart, Mireia"],"dc:date":["2013"],"dc:date.issued":["2013"],"dc:description":["Amphotericin B (AmB) is a drug used to treat visceral leishmaniasis and fungal infections. Current available AmB formulations are limited by instability at tropical temperature, parenteral administration, renal toxicity (Fungizone®) or cost (AmBisome®, Amphotec® and Abelcet®). In this study, inhaled AmB non-ionic surfactant vesicles (AmB-NIV) were assessed as an alternative AmB formulation, which should reduce costs, enhance drug bioavailability and stability and allow a non-invasive route of administration. AmB-NIV formulations (freshly prepared or lyophilised and non-ultra-filtrated or ultra-filtrated) were characterised on the basis of their vesicle size, ζ-potential, entrapment efficiency and viscosity. High performance liquid chromatography (HPLC) methods were validated and used to quantify the formulation constituents (AmB, cholesterol, surfactant and dicetyl phosphate) in stability studies. AmB-NIV formulations maintained stable at 37oC based on vesicle size, ζ-potential, entrapment efficiency and ingredients concentration up to 28 days. NIV enhanced drug delivery based on in vitro studies using a multi stage liquid impinger (MSLI) and should have lower toxicity based on the aggregation state of AmB. In vivo studies assessing the efficacy of inhaled AmB-NIV into a murine model of visceral leishmaniasis showed that 4 doses of inhaled AmB-NIV significantly reduced liver parasite burdens compared to the controls (p<0.05). Thus, NIV can be used to delivery AmB for the treatment of leishmaniasis by the pulmonary route but a multi-dose regimen is required."],"dc:description.abstract":["Amphotericin B (AmB) is a drug used to treat visceral leishmaniasis and fungal infections. Current available AmB formulations are limited by instability at tropical temperature, parenteral administration, renal toxicity (Fungizone®) or cost (AmBisome®, Amphotec® and Abelcet®). In this study, inhaled AmB non-ionic surfactant vesicles (AmB-NIV) were assessed as an alternative AmB formulation, which should reduce costs, enhance drug bioavailability and stability and allow a non-invasive route of administration. AmB-NIV formulations (freshly prepared or lyophilised and non-ultra-filtrated or ultra-filtrated) were characterised on the basis of their vesicle size, ζ-potential, entrapment efficiency and viscosity. High performance liquid chromatography (HPLC) methods were validated and used to quantify the formulation constituents (AmB, cholesterol, surfactant and dicetyl phosphate) in stability studies. AmB-NIV formulations maintained stable at 37oC based on vesicle size, ζ-potential, entrapment efficiency and ingredients concentration up to 28 days. NIV enhanced drug delivery based on in vitro studies using a multi stage liquid impinger (MSLI) and should have lower toxicity based on the aggregation state of AmB. In vivo studies assessing the efficacy of inhaled AmB-NIV into a murine model of visceral leishmaniasis showed that 4 doses of inhaled AmB-NIV significantly reduced liver parasite burdens compared to the controls (p<0.05). Thus, NIV can be used to delivery AmB for the treatment of leishmaniasis by the pulmonary route but a multi-dose regimen is required."],"dc:identifier":["T13480"],"dc:identifier.doi":["10.48730/8xfc-j642"],"dc:identifier.uri":["https://stax.strath.ac.uk/concern/theses/6h440s459"],"dc:publisher.department":["Strathclyde Institute of Pharmacy and Biomedical Sciences"],"dc:publisher.institution":["University of Strathclyde"],"dc:title":["Non-ionic surfactant vesicles as an Amphotericin B inhaled delivery system for the treatment of leishmaniasis"],"dc:type.qualificationlevel":["masters-pg"],"dc:type.qualificationname":["mres"]},"updated_at":"2026-07-24T04:42:25Z"}